Prof Demetri describes two key presentations from ASCO 2010: the rapid progress made developing a therapy for ALK mutation related non-small cell lung cancer patients and the encouraging results of a phase I study into inflammatory myofibroblastic tumour patients with the ALK mutation. Prof Demitri goes on to discuss his current research into the Hsp90 pathway, kinase inhibitors, cancer profiling and IGF-1 receptor agonists.